Vitamin D is cheap.
It is not regulated.
It is easily available.
It cannot be patented.
Big Pharma hates things like this.
Now comes bad news for Big Pharma: a scientific study indicates that vitamin D reduces colorectal cancer. This study is a real pain in the butt for Big Pharma.
Researchers from the Dana-Farber Cancer Institute have shown in a new study that vitamin D can help the body fight against colorectal cancer by boosting the immune system.
Vitamin D is naturally produced by the body following exposure to sunlight.
The study, published in Gut, contributes to a growing body of research by identifying an association between vitamin D and how the immune system responds to cancer cells among a large human population sample for the first time.
This was a punch in the gut for Big Pharma.
Colorectal cancer is the third most common cancer and fourth leading cause of cancer death worldwide, according to background information in the study. In the US, it is the second leading cause of cancer death. The Centers for Disease Control and Prevention (CDC) report that 51,783 people died from the disease in 2011.
Previous research has indicated that vitamin D could have a preventive effect against colorectal cancer. The vitamin is obtained through exposure to sunlight as well as certain foods and supplements.
The role of vitamin D within the body is to assist the immune system and contribute to calcium absorption and the growth and repair of bones. Some studies have also associated vitamin D with reducing the risk of multiple sclerosis, asthma symptoms and heart attacks.
“People with high levels of vitamin D in their bloodstream have a lower overall risk of developing colorectal cancer,” says senior author Dr. Shuji Ogino. “Laboratory research suggests that vitamin D boosts immune system function by activating T cells that recognize and attack cancer cells.”
Now Big Pharma will have to fund a study that proves that this study was not conducted properly, that it did not meet scientific standards.